X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Market Moves

Gerresheimer raises revenue guidance for 2022 to double-digit growth after strong first quarter

Content Team by Content Team
8th April 2022
in Market Moves

Gerresheimer AG, a leading provider of healthcare & beauty solutions and drug delivery systems for pharma, biotech and cosmetics, made a strong start to its 2022 fiscal year. The company delivered double-digit growth in both revenue and adjusted EBITDA in the first quarter and raises its 2022 revenue guidance. “We delivered an excellent first quarter demonstrating that our growth investments are paying off”, said Dietmar Siemssen, CEO of Gerresheimer AG. In the first quarter, all divisions contributed double-digit revenue growth. “Gerresheimer is on-track to achieve another record year”, Siemssen added. “We have a strong order book and experience increasing demand for existing as well as new products and solutions. The development gives us the confidence to raise our revenue guidance for 2022 to double-digit organic revenue growth.” Previously, Gerresheimer guided for high single-digit organic revenue growth in 2022.

In the first quarter of fiscal year 2022, Gerresheimer group generated revenues of 371m Euro with an organic growth rate of 19.1%. Our focus on investing in key growth drivers, such as High Value Solutions in pharma and beauty, Regional Expansion und Contract Manufacturing, paid off and all divisions achieved double-digit growth as a result. Revenue growth was also supported by the current dynamic pricing environment. Adjusted EBITDA rose to EUR 62m. Without considering FX effects organic growth was 10.6%. Adjusted earnings per share rose organically to 0.64 Euro with an organic growth rate of 8.5%.

Gerresheimer continues to successfully navigate through the current inflationary business environment by making use of its pricing power and benefitting from its long-term hedging strategy against volatile energy prices. At the same time, Gerresheimer continues to improve the energy mix in its facilities in line with its sustainability strategy.

In the Primary Packaging Glass Division sales were up by 21.8% organically pushed by strong demand for our High Value Solutions and high-quality ready-to-fill vials. The adjusted EBITDA grew organically by 11.1%.

The Plastics & Devices Division revenues grew organically by 16.9%, based on a strong performance in all business units. The adjusted EBITDA increased organically by 15.3%.

The Advanced Technologies Division performed as expected with a slight increase in revenues and adjusted EBITDA on prior year’s levels. For this financial year, Gerresheimer expects support through the development of the new pump for a large US biotech company focussing on rare diseases, a contract announced in December 2021.

Based on the successful development in the first quarter and the strong order book, Gerresheimer has raised its guidance for organic revenue growth in 2022.

About Gerresheimer

Gerresheimer is the global partner for pharmaceutics, biotech, healthcare, and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging solutions and drug delivery systems. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 10,000 employees and generated annual revenues in 2021 of around EUR1.5b. With its products and solutions, Gerresheimer plays an essential role in people’s health and well-being.

Previous Post

Envirotainers Releye RAP container already approved by 10 airlines

Next Post

Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates

Related Posts

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m
Market Moves

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m

18th July 2022
Could The Long Deckline In Biotechnology M&A Be Ending
Featured

Could The Long Deckline In Biotechnology M&A Be Ending

16th July 2022
EMA Advises Recall of AbbVie, Biogen MS Drug
Market Moves

No Rush In Indian Generic Drug Firms To Launch COVID Products

16th July 2022
Regeneron, Intellia to develop CRISPR/Cas9-based treatments
Market Moves

Metagenomi Closes Oversubscribed $175M Series B Financing to Advance Therapeutic Pipeline and Expand Novel Gene Editing Platform

29th January 2022
Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe
Market Moves

Indian Pharma Industry To Grow By 9-11% In FY22- ICRA

7th January 2022
Market Moves

IQVIA Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance

26th October 2021
Next Post
U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA

Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates

Latest News

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
FDA Approvals

Food And Drug Administration User Fee Has Been Reauthorized

3rd November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In